에 대한 최신 뉴스 Novartis (NYSE:NVS) 주식

Novartis

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Earnings

Equities

News

Pre-Market Outlook

Markets

Trading Ideas

NFLX

목요일 아침 (동부 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 D.R. 호튼(NYSE:DHI)이 개장 전 매출 97억 7천만 달러, 주당 3.77달러의 분기 이익을 보고할 예정이다. 벤징가 프로의 데이터에 따르면 D.R. 호튼의 주식은 시간외 거래에서 0.3% 상승한 158.00달러를 기록했다.

목요일 주목해야 주식: D.R. 호튼, 노바티스, 넷플릭스 그리고  2종목

Novartis AG

NEVADA SUNRISE METALS CRP by NEVADA SUNRISE METALS CORP.

Nevada Sunrise Metals Corp

NOVUS HLDGS LTD SHS by NOVUS HLDGS LTD SHS

Novus Holdings Ltd

Envista Holdings Corporation Common Stock

Envista Holdings Corp

Biotech

Global

General

NVAX

World Organization For Animal Health Says Hungary And Italy Report Farm Outbreaks Of Highly Pathogenic H5N1 Bird Flu

Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective from October 1, 2024, to December 31, 2024.
The <a target="_blank" href="https://www.hhs.gov/about/news/2024/09/30/hhs-announces-cost-savings-for-prescription-drugs-thanks-to-medicare-inflation-rebate-program.html" rel="noreferrer noopener">program</a> aims to counter drug price hikes that exceed inflation, providing financial relief for over 822,000 Medicare beneficiaries who rely on these medications to treat conditions like cancer, osteoporosis, and pneumonia.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422798/doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy" rel="noreferrer noopener">Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk&#8217;s Wegovy</a>
HHS Secretary Xavier Becerra emphasized that the Biden administration&#8217;s prescription drug policies are making a tangible impact on seniors and people with disabilities by reducing out-of-pocket costs.
According to Chiquita Brooks-LaSure, CMS Administrator, some Medicare beneficiaries could see daily savings ranging from $1 to as much as $3,854 on drugs included in the rebate program.
For example, a cancer patient using Novartis&#8217; AGs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Kymriah could save up to $3,000.
Brooks-LaSure also noted that the law disincentivizes drug companies from raising prices faster than inflation, which helps protect Medicare beneficiaries from sharp price increases.
The Inflation Reduction Act&#8217;s initiatives extend beyond 2024. In August, the administration reached new agreements to reduce prices for ten additional high-cost drugs.
Once these prices take effect in 2026, Medicare is projected to save an estimated $6 billion, while beneficiaries could see a reduction of $1.5 billion in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40397706/biden-administration-targets-6b-savings-through-medicare-drug-price-negotiations" rel="noreferrer noopener">out-of-pocket expenses</a>.
Starting in 2025, Medicare Part D enrollees will further benefit from a $2,000 annual cap on prescription drug costs, down from the current cap of $3,500 for those with high expenses.
According to some analysts,&nbsp;Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)&nbsp;blockbuster diabetes drug&nbsp;Ozempic might be included, along with several other well-known medications, in the next round of negotiations, which <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">is set for 2027</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41124151/tpg-gic-agree-to-buy-techem-for-7-5b-look-to-expand-across-europe-and-beyond" target="_blank" rel="noreferrer noopener">TPG, GIC Agree To Buy Techem For $7.5B: Look To Expand &#8216;Across Europe And Beyond&#8217;</a></li>
</ul>
Photo via Shutterstock

Government

Large Cap

Regulations

Health Care

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next

Macro Economic Events

Economics

World Organization For Animal Health Says Germany Reports Outbreak Of Highly Pathogenic H5N1 Bird Flu On Farm In Eastern Part Of The Country

Under the terms of the collaboration agreement, Generate will receive a total upfront payment of&nbsp;$65 million&nbsp;in cash from Novartis, which includes&nbsp;$15 million&nbsp;for the purchase of equity in Generate. Generate is also eligible to receive more than&nbsp;$1 billion&nbsp;in performance-based milestone payments, in addition to tiered royalties up to low double-digits. The number of targets and therapeutic areas are not being disclosed.

Contracts

Generate:Biomedicines Enters Multi-target Collaboration With Novartis To Discover, Develop Protein Therapeutics Across Multiple Disease Areas; Potential Total Transaction Valued At More Than $1B

Truist Securities has downgraded Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), noting Jakafi&#8217;s (ruxolitinib) patent loss <a target="_blank" href="https://www.benzinga.com/quote/INCY" rel="noreferrer noopener">approaching in 2028</a>.
Jakafi is Incyte&#8217;s top-selling drug. It is indicated for polycythemia vera in adults, intermediate or high-risk myelofibrosis in adults, and steroid-refractory acute graft versus host disease in adult and pediatric patients.
In second quarter 2024, the drug generated sales of&nbsp;$705.9 million, +3% year-over-year, driven by a 9% <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40045943/incytes-q2-earnings-wider-than-expected-loss-pipeline-review-lifts-jakafi-sales-gui" rel="noreferrer noopener">increase in paid demand</a>.
The analyst downgraded the stock from Buy to Hold, with a price target of $74, <a target="_blank" href="https://www.benzinga.com/quote/INCY/analyst-ratings" rel="noreferrer noopener">down from $83</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40417124/incyte-seeks-expanded-fda-approval-for-lymphoma-drug-after-releasing-promising-topline-data-from-" rel="noreferrer noopener">Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study</a>.
With Jakafi&#8217;s loss of exclusivity approaching, a key concern is whether Incyte&#8217;s pipeline in immunology, inflammation (I&amp;I), and oncology can compensate for the revenue decline expected from generic competition. While there is long-term growth potential in the company&#8217;s pipeline—supported by strong Phase 2 data and opportunities for expansion into new indications or combination therapies—the challenge of mitigating the patent cliff remains significant.
Additionally, Incyte faces intense competition, particularly in larger markets where it aims to establish a foothold, such as I&amp;I and solid tumors.
Truist emphasizes the significance of the late-stage results for Povorcitinib in hidradenitis suppurativa (HS), expected in the first half of 2025, as a key factor likely to influence stock performance over the next 12 months.
Additionally, the analyst draws attention to the earlier-stage results expected in the second half of 2024 for Zilurgisertib in myelofibrosis. However, due to Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) delays and the challenges, combined with the early development stage of Incyte&#8217;s programs, Truist is adopting a more cautious stance.
Price Action: INCY stock is down 0.93% at $65.81 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40923696/general-motors-boosts-ev-charging-access-17-800-tesla-chargers-now-open-for-all-gm-drivers-with-" target="_blank" rel="noreferrer noopener">General Motors Boosts EV Charging Access: 17,800 Tesla Chargers Now Open For All GM Drivers With New Adapter</a>.</li>
</ul>

Analyst Color

Downgrades

Price Target

Analyst Ratings

INCY

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets

Novartis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.
The regulatory body approved Kisqali in combination with an aromatase inhibitor for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence, including those with node-negative (N0) disease.
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that helps slow the progression of cancer by inhibiting two proteins &mdash; cyclin-dependent kinase 4 and 6 (CDK4/6).
The broad indication in HR+/HER2- stage II and III EBC at high risk of recurrence approximately doubles the population eligible for CDK4/6 inhibitor adjuvant therapy.
Year to date, shares of Novartis have risen 14.6% compared with the industry&#39;s growth of 24.1%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e0/78240.jpg?v=1246149801" /> 
Image Source: Zacks Investment Research
<h2>Broader Label for NVS&#39; Kisqali</h2>
The FDA approval is based on strong results from the late-stage NATALEE trial. The results showed a significant and clinically meaningful 25.1% reduction in risk of disease recurrence in a broad population of patients with HR+/HER2- stage II and III EBC treated with adjuvant Kisqali plus endocrine therapy&nbsp;compared to ET alone, including those with high-risk N0 disease.
The invasive disease-free survival benefit was consistently observed across all patient subgroups.
Please note that Kisqali is already approved for the treatment of metastatic breast cancer (MBC) in several countries.
The latest FDA approval of Kisqali for this early breast cancer population, including those with N0 disease, should enable NVS to offer treatment with a CDK4/6 inhibitor to a significantly broader group of patients.
NVS recently presented an updated analysis from the NATALEE trial at the European Society for Medical Oncology Congress 2024. Results showed that Kisqali caused a deepening benefit beyond the three-year treatment period and reduced the risk of recurrence by 28.5% compared to ET alone, in patients with stage II and III HR+/HER2- EBC.
Novartis will continue to evaluate NATALEE patients for long-term outcomes, including overall survival.
<h2>Kisqali: A Top Drug for NVS</h2>
Kisqali is one of the key growth drivers for NVS, which is now a pure-play innovative medicine company with a focus on core therapeutic areas &mdash; cardiovascular, renal and metabolic, immunology, neuroscience and oncology.
It is one of the leading breast cancer drugs in the United States and outside the country, with a dominant market share. The drug generated sales worth $1.3 billion in the first half of 2024.
Approximately 90% of breast cancer cases in the United States are diagnosed early (stages I-III). These patients remain at risk of cancer recurrence (in most cases as an incurable metastatic disease).
The drug&#39;s approval for a broader population should further fuel sales.
Regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.
Last year, the FDA also expanded Eli Lilly&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) Verzenio&#39;s (abemaciclib) indication. Verzenio, a CDK4/6 inhibitor, was approved in combination with ET for the adjuvant treatment of HR+HER2-, node-positive, EBC at a high risk of recurrence.
Eli Lilly is witnessing a stupendous run in 2024, riding high on the success of its GLP-1 drugs &mdash; Mounjaro and Zepbound.
<h2>NVS&#39; Zacks Rank &amp; A Stock to Consider</h2>
NVS currently carries a Zacks Rank #3 (Hold).
A better-ranked stock from the large-cap pharma industry is Pfizer, which currently sports a Zacks Rank #2 (Buy).
Estimates for PFE&#39;s 2024 earnings have risen from $2.39 to $2.62 per share over the past 60 days. For 2025, the bottom-line estimate has risen from $2.75 to $2.85 over the same time frame.
<a href="https://www.zacks.com/stock/news/2337925/novartis-wins-fda-approval-of-kisqali-for-early-breast-cancer?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2337925">To read this article on Zacks.com click here.</a>

Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) released new data Wednesday from the ALITHIOS open-label extension study.
Data show first-line Kesimpta&nbsp;(ofatumumab) treatment for up to six years led to less disability and disease progression in recently diagnosed (≤3 years) and treatment-naïve (RDTN) people with relapsing multiple sclerosis (RMS), compared to those who switched from Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Aubagio (teriflunomide).
These <a target="_blank" href="https://www.novartis.com/news/media-releases/new-novartis-data-relapsing-ms-reinforce-benefits-kesimpta-first-line-and-switch-patients" rel="noreferrer noopener">data</a> will be presented at the European Committee for Treatment and Research in Multiple Sclerosis.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40738489/goldman-sachs-shifts-stance-on-novartis-cites-lack-of-near-term-catalysts" rel="noreferrer noopener">Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts</a>.
Data from the overall ALITHIOS study population showed that continuous use of Kesimpta was associated with numerically fewer six-month confirmed disability worsening (6mCDW) and progression independent of relapse activity (6mPIRA) events up to six years compared to those who switched from teriflunomide.
RDTN patients receiving continuous Kesimpta were more likely to remain free from 6mCDW than those who switched to Kesimpta from teriflunomide (83.4% vs. 76.3%).
RDTN patients receiving continuous Kesimpta were also more likely to be free of 6mPIRA vs. switching from teriflunomide (88.9% vs. 83.3%).
A separate U.S.-based single-arm OLIKOS Phase 3b study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new gadolinium-enhancing (Gd+) T1 lesions, a commonly used marker of disease activity, compared to baseline.
Tuesday, the FDA <a target="_blank" href="https://www.novartis.com/news/media-releases/fda-approves-novartis-kisqali-reduce-risk-recurrence-people-hrher2-early-breast-cancer" rel="noreferrer noopener">approved</a> Novartis&#8217; Kisqali&nbsp;(ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative stage II and III early breast cancer at high risk of recurrence, including those with node-negative disease.
The approval is based on results from the pivotal Phase 3 NATALEE trial, which showed a significant and clinically meaningful 25.1% reduction in risk of disease recurrence.
Price Action: Novartis stock is down 0.1% at $115.85 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40922004/tupperware-seeks-bankruptcy-protection-as-demand-for-its-colorful-containers-fades-in-the-e-comm" target="_blank" rel="noreferrer noopener">Tupperware Seeks Bankruptcy Protection As Demand For Its Colorful Containers Fades In The E-Commerce Era</a></li>
</ul>
Image: Wikimedia Commons

Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years

Novartis Announced New Data From ALITHIOS Open-label Extension Study, Showing First-line Kesimpta (Ofatumumab) Treatment For Up To Six Years Led To Less Disability And Disease Progression In Recently Diagnosed And Treatment-naïve Relapsing Multiple Sclerosis Patients Vs. Those Who Switched From Teriflunomide

The FDA Approves Novartis' Kisqali (Ribociclib) In Combination With An Aromatase Inhibitor For The Adjuvant Treatment Of Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Stage II And III Early Breast Cancer At High Risk Of Recurrence

Eli Lilly and Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved for use in adults and children aged 12 and above who weigh at least 40 kgs and whose moderate-to-severe atopic dermatitis is not well controlled with topical prescription medicines.
Ebglyss was approved in the European Union in 2023 and in Japan in January this year. The drug generated sales of $7.5 million in the first half of 2024.
Year to date, Lilly&#39;s stock has risen 58.5% compared with the industry&#39;s 25.2% growth. The stock has also outperformed the sector as well as the S&amp;P 500.
<h2>LLY Stock Outperforms Industry, Sector &amp; S&amp;P 500</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/93/77794.jpg?v=624696101" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>More on LLY&#39;s Ebglyss</h2>
Ebglyss&#39; approval in the United States was based on data from&nbsp;ADvocate 1, ADvocate 2 and ADhere studies. Data from these studies showed that patients treated with Ebglyss experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeks. Many people living with eczema experience poor long-term disease control and severe itch despite treatment with topicals. Ebglyss offers such patients a new first-line biologic treatment option for treating their moderate-to-severe eczema. The injection will be launched in the United States in the coming weeks.
In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to Ebglyss. However, in Europe, it has out-licensed rights to develop and commercialize Ebglyss for the treatment of dermatology indications to its partner Almirall.
<h2>Lilly&#39;s Several New Drug Approvals in Past Year</h2>
Lilly gained approvals for some other new drugs in the past year, with the most important being Mounjaro and Zepbound. &nbsp;Mounjaro and Zepbound include the same compound, tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA). Mounjaro was approved in May 2022 for type II diabetes. Zepbound was launched in November 2023 to treat obesity.
Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly in 2024, with demand rising rapidly. Mounjaro and Zepbound generated sales of almost $6.7 billion in the first half of 2024, accounting for around 44% of the company&#39;s total revenues.
Other than Mounjaro and Zepbound, other new drug approvals include Omvoh for ulcerative colitis and BTK inhibitor Jaypirca for mantle cell lymphoma and chronic lymphocytic leukemia. Lilly expects its new drugs &mdash; Mounjaro, Omvoh, Zepbound, Ebglyss and Jaypirca &mdash; to drive its top line in the second half of 2024.
In July, Lilly won a long-awaited FDA approval for Kisunla (donanemab) for treating early symptomatic Alzheimer&#39;s disease. Lilly believes Kisunla can generate blockbuster sales. Kisunla is only the second drug on the market to treat Alzheimer&#39;s disease after Biogen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) and its Japan-based partner Eisai&#39;s Leqembi.
<h2>Lilly&#39;s Zacks Rank and Other Stocks to Consider</h2>
Lilly sports a Zacks Rank #1 (Strong Buy).
<div class="chart_embed">
<h3>Eli Lilly and Company Stock Price and Consensus</h3>
<img alt="Eli Lilly and Company Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/84/1726472114.png" style="height:265px; width:591px" title="" />
Eli Lilly and Company price-consensus-chart | Eli Lilly and Company Quote
Some other top-ranked large drugmakers are Novartis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) and Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>), each carrying a Zacks Rank #2 (Buy).
</div>
In the past 60 days, 2024 earnings estimates for Pfizer have improved from $2.38 per share to $2.62 per share. For 2025, earnings estimates have improved from $2.75 per share to $2.85 per share over the same timeframe. Pfizer shares have risen 1.6% year to date.
Pfizer&#39;s earnings beat estimates in each of the last four quarters. PFE delivered a four-quarter average earnings surprise of 69.82%
Estimates for Novartis&#39; 2024 earnings have risen from $7.31 to $7.50 per share over the past 60 days. For 2025, earnings estimates have increased from $8.21 to $8.29 per share over the same timeframe. Year to date, Novartis stock has risen 14.5 %.
Novartis beat estimates in three of the last four quarters while missing in one, delivering a four-quarter average earnings surprise of 1.26%.
<a href="https://www.zacks.com/stock/news/2336877/lilly-gets-fda-approval-for-eczema-drug-ebglyss?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2336877">To read this article on Zacks.com click here.</a>

BIIB

Lilly Gets FDA Approval for Eczema Drug Ebglyss

FDA Approves Novartis Kisqali To Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer

In An Updated Analysis From Phase 3 NATALEE Trial Of Novartis' Kisqali (Ribociclib) Added To Endocrine Therapy Shows Deepening Benefit Beyond Three-year Treatment Period, Reducing Risk Of Recurrence By 28.5%, Compared To ET Alone, For Stage II And III Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02a43eaaa00018d939e/edward-white">HC Wainwright &amp; Co. analyst Edward White</a> downgraded the rating for Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Buy to Neutral. Adicet Bio shares fell 3.4% to close at $1.43 on Tuesday. <a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">See how other analysts </a><a href="https://www.benzinga.com/quote/ACET/analyst-ratings">view </a><a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">this stock</a>.</li>
<li>B of A Securities analyst Graham Perry downgraded Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral and lowered the price target from $135 to $130. Novartis shares fell 0.2% to close at $116.99 on Tuesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/topic/david-amsellem">Piper Sandler analyst David Amsellem</a> downgraded the rating for Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and cut the price target from $41 to $36. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. <a href="https://www.benzinga.com/quote/SUPN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Gregory Fraser downgraded ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) from Buy to Hold and slashed the price target from $80 to $60. ANI Pharmaceuticals shares fell 5.1% to close at $55.48 on Tuesday. <a href="https://www.benzinga.com/quote/ANIP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NVS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png" alt="" class="wp-image-542353" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88.png 1292w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:<a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock">Jim Cramer Says AES Is &#8216;Very Inexpensive&#8217;, Recommends Buying This Industrial Stock</a></li>
</ul>

ACET

ANIP

RLAY

SUPN

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Ascendiant Capital raised the price target for Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) from $6.25 to $6.5. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Atossa Therapeutics shares gained 7.4% to close at $1.46 on Tuesday. <a href="https://www.benzinga.com/quote/atos/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from $135 to $130. B of A Securities analyst Graham Perry downgraded the stock from Buy to Neutral. Novartis shares fell 0.2% to close at $116.99 on Tuesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Camden National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NYSE">CAC</a>) price target from $40 to $41. Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintained a Market Perform rating. Camden National shares fell 0.3% to close at $37.78 on Tuesday. <a href="https://www.benzinga.com/quote/CAC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) price target from $41 to $36. Piper Sandler analyst David Amsellem downgraded the stock from Overweight to Neutral. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. <a href="https://www.benzinga.com/quote/SUPN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from $100 to $120. B of A Securities analyst Omar Dessouky maintained a Buy rating. AppLovin shares fell 0.1% to close at $86.23 on Tuesday. <a href="https://www.benzinga.com/quote/APP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel boosted Krystal Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) price target from $204 to $220. Stifel analyst Dae Gon Ha maintained a Buy rating. Krystal Biotech shares fell 1.4% to close at $185.00 on Tuesday. <a href="https://www.benzinga.com/quote/KRYS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital cut Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) price target from $65 to $55. BMO Capital analyst Andrew Strelzik maintained an Outperform rating. Dave &amp; Buster&#8217;s shares fell 0.8% to close at $29.86 on Tuesday. <a href="https://www.benzinga.com/quote/PLAY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut the price target for GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) from $11 to $10. Wedbush analyst Michael Pachter maintained an Underperform rating. GameStop shares fell 3.3% to close at $23.45 on Tuesday. <a href="https://www.benzinga.com/quote/GME/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) price target from $60 to $63. Truist Securities analyst Joseph Civello maintained a Buy rating. Academy Sports shares gained 5.2% to close at $55.38 on Tuesday. <a href="https://www.benzinga.com/quote/ASO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital cut Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $525 to $510. BMO Capital analyst Andrew Strelzik maintained an Outperform rating. Domino&#8217;s shares fell 0.8% to close at $416.77 on Tuesday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DPZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-1024x534.png" alt="" class="wp-image-542314" style="width:481px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87.png 1276w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

ATOS

KRYS

PLAY

Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday

WIIM

Novartis shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and lowered its price target to $130.

B of A Securities analyst Graham Perry downgrades Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral and lowers the price target from $135 to $130.

B of A Securities Downgrades Novartis to Neutral, Lowers Price Target to $130

HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) and noted the company as an emerging biotech company developing next-gen precision-oriented small molecules for solid and <a target="_blank" href="https://www.benzinga.com/quote/ELVN" rel="noreferrer noopener">liquid tumor indications</a>.
Enliven&#8217;s pipeline includes:
<ul>
<li>ELVN-001— a tyrosine kinase inhibitor (TKI) targeting mutant BCR::ABL. HC Wainwright highlights that ELVN-001 could meaningfully improve on existing TKI drugs used in chronic myelogenous leukemia, with applicability across multiple lines of therapy.</li>
<li>In April, the company released proof of concept data from the Phase 1 trial of ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or <a href="https://www.benzinga.com/general/biotech/24/04/38208363/enliven-therapeutics-shares-first-look-at-safety-clinical-activity-of-lead-program" target="_blank" rel="noreferrer noopener">intolerant to available TKIs</a>.</li>
<li>ELVN-001 achieved a cumulative major molecular response (MMR) rate of 44% (7/16) by 12 weeks and demonstrated responses in patients with prior exposure to asciminib and who were TKI-resistant.</li>
<li>ELVN-002 is being evaluated in combination with trastuzumab plus chemotherapy or as monotherapy in HER2-driven malignancies within non-small cell lung, colorectal, and metastatic breast cancer, among others.</li>
</ul>
The analyst initiates with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/ELVN/analyst-ratings" rel="noreferrer noopener">price target of $37</a>.
CML is a chronic disease requiring multiple years of continuous treatment. Patients frequently switch therapies due to liabilities of the existing approved drugs, including poor tolerability due to off-target effects and inability to dose to maximal efficacy.
Six approved drugs—Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Gleevec (imatinib), Scemblix (asciminib), and Tasigna (nilotinib), Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Sprycel (dasatinib), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Bosulif (bosutinib), and Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) Iclusig (ponatinib)—generate over $6 billion in annual sales, with each drug bringing in around $500 million. Some even achieve peak annual sales of up to $2 billion despite competition from generic versions.
HC Wainwright analyst projects that positioning ELVN-001 as a third-line treatment could surpass $500 million in peak annual sales.
ELVN-002 has the potential to address unmet needs in HER2-mutant NSCLC, CRC, and mBC, where current treatments have limitations. It could challenge competitors like Pfizer&#8217;s Tukysa and tap into the growing post-AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Enhertu market, with sales possibly reaching hundreds of millions.
While Enliven focuses on precision oncology, its target market is broader than that of past agents like Bristol-Myers&#8217; Augtyro (repotrectinib) and Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Rozlytrek (entrectinib).
Price Action: ELVN stock is up 7.32% at $23.01 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>.</li>
</ul>

Movers

ELVN

RHHBY

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

Goldman Sachs has downgraded Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), citing &#8220;limited value driving innovation catalysts <a target="_blank" href="https://www.benzinga.com/quote/NVs" rel="noreferrer noopener">in the near term</a>.&#8221;
The analyst writes that continued earnings momentum has led to increases in revenue and profit forecasts for fiscal years 2024 and 2025 since the beginning of the year, thanks to upgraded fiscal year 2024 guidance provided in the first and second quarters of 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40694793/despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs" rel="noreferrer noopener">Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs</a>.
Moreover, from a valuation standpoint, Novartis is trading at 14.2 times its projected 2025 EPS, representing an approximately 8% premium over the European Biopharma sector, excluding Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Goldman writes the premium has been higher than the average since 2023, which was about 7%, and it exceeds the premium at the time of our initial coverage, around 5%.
For the rest of the year, after <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml" rel="noreferrer noopener">presenting</a> the detailed Scemblix first-line chronic myeloid leukemia data at ASCO, the Goldman analyst writes that few catalysts are ahead, offering limited potential for substantial share price growth in the next 12 months.
With consensus estimates now aligned with Goldman Sachs&#8217; projections and anticipating a slowdown in significant news that could drive value until mid-2025, the analyst foresee minimal potential for substantial gains in the next 12 months. Consequently, the stock was <a target="_blank" href="https://www.benzinga.com/quote/NVS/analyst-ratings" rel="noreferrer noopener">downgraded from Buy to Neutral</a>.
Based on the current pace of repurchases, Novartis is on track to finalize its $15 billion buyback initiative between the end of April and mid-May 2025. Since the program&#8217;s launch in July 2023, the company&#8217;s stock has appreciated by 25%, suggesting that the effects of the share buyback are likely already incorporated into the stock price.
Consequently, further significant gains tied directly to this program are not expected. While introducing another buyback scheme could potentially boost the stock, such an announcement is unlikely before the second quarter of 2025, following the completion of the existing program.
Price Action: NVS stock is down 2.16% at $116.80 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40731728/eli-lillys-once-weekly-insulin-shows-non-inferior-blood-sugar-reduction-vs-frequently-used-daily-" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs. Frequently Used Daily Insulins In Long Term Trials</a>.</li>
</ul>

Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Piper Sandler cut the price target for C3.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from $29 to $24. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. C3.ai shares fell 1.9% to close at $23.01 on Wednesday. <a href="https://www.benzinga.com/quote/AI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised the price target for Collegium Pharmaceutical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) from $47 to $50. HC Wainwright &amp; Co. analyst Oren Livnat maintained a Buy rating. Praxis Collegium Pharmaceutical shares gained 2.2% to close at $38.24 on Wednesday. <a href="https://www.benzinga.com/quote/COLL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) price target from $3 to $2. Needham analyst Chris Pierce maintained a Buy rating. ChargePoint shares fell 0.6% to close at $1.69 on Wednesday. <a href="https://www.benzinga.com/quote/CHPT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) price target from $530 to $564. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. S&amp;P Global shares gained 0.5% to close at $513.31 on Wednesday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital cut the price target for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from $130 to $68. BMO Capital analyst Kelly Bania downgraded the stock from Outperform to Market Perform. Dollar Tree shares fell 22.2% to close at $63.56 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) price target from $119 to $121. Goldman Sachs analyst James Quigley downgraded the stock from Buy to Neutral. Novartis shares rose 0.7% to close at $119.38 on Wednesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Core &amp; Main, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) price target from $62 to $53. Baird analyst David Manthey maintained an Outperform rating. Core &amp; Main shares fell 15.8% to close at $39.40 on Wednesday. <a href="https://www.benzinga.com/quote/CNM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Susquehanna slashed the price target for EVERTEC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from $38 to $28. Susquehanna analyst James Friedman downgraded the stock from Neutral to Negative. EVERTEC shares rose 0.3% to close at $33.73 on Wednesday. <a href="https://www.benzinga.com/quote/EVTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) price target from $180 to $150. Piper Sandler analyst Charles Neivert downgraded the stock from Overweight to Neutral. Celanese shares fell 0.8% to close at $124.31 on Wednesday.<a href="https://www.benzinga.com/quote/CE/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Morgan Stanley lowered StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) price target from $16.5 to $7. Morgan Stanley analyst Jorge Kuri downgraded the stock from Equal-Weight to Underweight. StoneCo shares fell 3.8% to close at $12.61 on Wednesday.<a href="https://www.benzinga.com/quote/STNE/analyst-ratings"> See how other analysts view this stock.</a></li>
</ul>
Considering buying SPGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-1024x522.png" alt="" class="wp-image-531810" style="width:536px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36.png 1321w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

CHPT

COLL

DLTR

EVTC

SPGI

STNE

S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday

VYGR

Voyager Therapeutics Announces Novartis Licensing Novel Capsid From TRACER Platform For Use In Gene Therapy Targeting Undisclosed Rare Neurologic Disease​

Perspective Therapeutics a new buy at Wedbush on radiopharmaceutical assets

With inflation dropping to 2.2% in August 2024 and the potential for further interest rate cuts on the horizon, European markets could become more attractive as growth picks up. Thus, one could consider keeping an eye on fundamentally sound European stocks like Novartis (NVS), Unilever (UL), and Siemens Aktiengesellschaft (SIEGY). Read on… European shares have <a href="https://www.reuters.com/markets/europe/european-shares-flat-ahead-data-packed-week-2024-09-23/">recently risen</a>, driven by soft business activity data that strengthens the case for more monetary easing by the European Central Bank (ECB) this year. As the economy gradually finds its footing, adding fundamentally sound European companies such as Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>), Unilever PLC (<a href="https://stocknews.com/stock/UL/">UL</a>), and Siemens Aktiengesellschaft (<a href="https://stocknews.com/stock/SIEGY/">SIEGY</a>) to your watchlist could be wise.
In early 2024, the euro area saw modest growth, with GDP expanding by <a href="https://ec.europa.eu/eurostat/web/products-euro-indicators/w/2-06092024-ap#:~:text=In%20the%20second%20quarter%20of,by%200.3%25%20in%20both%20zones.">0.2% in the second quarter</a>. While this may not seem like much, the fact that the economy has shifted from stagnation to growth is a promising signal for investors. However, this recovery has been uneven. While sectors like exports and government spending have bolstered growth, domestic demand remains sluggish, with consumers hesitant and businesses cautious about new investments.
As interest rates fall, the cost of borrowing will decrease, encouraging both consumers and businesses to start spending more freely. Christine Lagarde, President of the ECB, expressed optimism that as real incomes rise and inflation cools, we could see stronger consumption in the coming years. The ECB projects the economy to grow by <a href="https://www.ecb.europa.eu/press/key/date/2024/html/ecb.sp240930~c4da646c0d.en.html#:~:text=The%20outlook%20for%20the%20euro,economic%20activity%20broadly%20stagnated%20thereafter.">0.8% in 2024</a>, 1.3% in 2025 and 1.5% in 2026.
Moreover, with inflation dropping to 2.2% in August 2024 and further declines expected due to falling energy prices, consumer spending could increase as savings become less attractive. This, in turn, could drive future economic growth.
With that in mind, let's look at the fundamental aspects of the above-mentioned stocks in detail:
Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>)
Headquartered in Basel, Switzerland, NVS researches, develops, manufactures, and markets healthcare products worldwide through two segments: Innovative Medicines and Sandoz.
On August 28, the company's subsidiary Novartis Pharma AG entered into a global licensing agreement with Lindy Biosciences to access its innovative microglassification technology for biologic drugs. This partnership grants NVS exclusive global rights across multiple biologic targets, focusing on developing high-concentration, self-administered treatments.
The collaboration aims to improve patient outcomes and compliance by enabling at-home treatments. Further, it strengthens the company's position in innovative drug delivery and enhances its ability to offer patient-friendly solutions.
NVS pays an annual dividend of $3.74 per share, translating to a yield of 3.25% at the current price level, while its four-year average yield is 3.49%. Its dividend payouts have increased at a 7.3% CAGR over the past three years and a 6.9% CAGR over the past five years.
In the fiscal second quarter that ended June 30, 2024, NVS' net sales increased 9.4% year-over-year to $12.51 billion. Its operating income from continuing operations grew 43% from the year-ago value to $4.01 billion. The company's <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> and EPS came in at $3.25 billion and $1.60, representing a 40.1% and 44.1% year-over-year improvement, respectively. In addition, its free cash flow stood at $4.62 billion, up 40.9% year-over-year.
The consensus EPS estimate of $1.96 for the fiscal third quarter (ended September 2024) represents a 12.5% improvement year-over-year. The consensus revenue estimate of $12.52 billion for the same quarter represents a 6.3% increase from last year. The company has an impressive surprise history; it surpassed the consensus revenue estimates in three of the trailing four quarters.
NVS shares have surged 18.2% over the past six months to close the last trading session at $115.02.
NVS' bright prospects are reflected in its<a href="https://stocknews.com/powr-ratings/"> POWR Ratings</a>. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
NVS has a B grade for Growth, Value, Stability, Sentiment, and Quality. It is ranked #2 out of 159 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/NVS/">Click here</a> to see NVS' ratings for Momentum.
Unilever PLC (<a href="https://stocknews.com/stock/UL/">UL</a>)
UL is a United Kingdom-based fast-moving consumer goods (FMCG) company that operates through five segments: Beauty &amp; Wellbeing; Personal Care; Home Care; Nutrition; and Ice Cream.
In July, the company announced the sale of its stake in Qinyuan Group to Yong Chao Venture Capital Co., Ltd., aiming to refine its portfolio for higher-growth sectors under its Growth Action Plan. Qinyuan.
In the same month, UL also sold its water purification business, Pureit, to A. O. Smith, enhancing its global water technology offerings.
Such transactions enable the company to focus on more lucrative opportunities while leveraging the expertise of specialized companies to enhance the growth potential of its former water purification brands.
For the first half of the year ended June 30, 2024, UL's turnover increased 2.3% year-over-year to €31.12 billion ($34.74 billion). Its operating profit rose 7.8% from the prior year's quarter to €5.95 billion ($6.64 billion), while its net profit stood at €4.02 billion ($4.48 billion), up 3.5% year-over-year. Also, its earnings per share for the period came in at €1.47, representing an increase of 5.4% year-over-year.
Analysts expect UL's revenue for the current year (ending December 2024) to grow 5.1% year-over-year to $67.50 billion, while its EPS for the same period is expected to increase 11.2% from the prior year to $3.12. For the fiscal year 2025, both revenue and EPS are anticipated to register a year-over-year growth of 3.6% and 8.5%, respectively.
Over the past nine months, the stock has gained 32.8%, closing the last trading session at $64.96.
UL's strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It has a B grade for Stability and Sentiment. UL is ranked #9 out of 55 stocks in the B-rated <a href="https://stocknews.com/category/consumer-goods/">Consumer Goods</a> industry. <a href="https://stocknews.com/stock/UL/">Click here</a> to see the additional UL ratings (Growth, Value, Momentum, and Quality).
Siemens Aktiengesellschaft (<a href="https://stocknews.com/stock/SIEGY/">SIEGY</a>)
Headquartered in Munich, Germany, SIEGY is a leading technology company that emphasizes automation and digitalization worldwide. The company operates through Digital Industries; Smart Infrastructure; Mobility; Siemens Healthineers; and Siemens Financial Services (SFS) segments.
On September 26, the company's Mobility segment signed a framework agreement with RS Lease, Slovakia's leading private lessor of railway vehicles, for the delivery of up to 65 Vectron locomotives. The agreement includes the swift delivery of 30 Vectron MS locomotives, with an option for an additional 35 locomotives across Vectron Multi System and Vectron Dual Mode variants.
This deal is expected to boost SIEGY's presence in Europe and drive revenue growth through increased demand for its Vectron locomotives.
In the same month, Siemens Mobility and U.S. Senate Majority Leader Chuck Schumer, Brightline West, announced plans to establish North America's first high-speed rail production facility in Horseheads, New York. This $60 million investment will produce the American Pioneer 220 high-speed trains, set to operate on the Las Vegas to Southern California route. Production at the facility is expected to begin in 2026.
For the fiscal 2024 third quarter that ended June 30, 2024, SIEGY's revenue increased 4.2% year-over-year to €18.90 billion ($21.09 billion). The company's gross profit rose 9% from the year-ago value to €7.75 billion ($8.65 billion). Its income from continuing operations came in at €2.16 billion ($2.41 billion), up 55.7% from the prior year's quarter.
In addition, SIEGY's net income for the quarter amounted to €2.13 billion ($2.38 billion), or €2.48 per share, representing a 48.1% and 55.9% year-over-year growth, respectively. Its free cash flow from continued and discontinued operations came in at €2.12 billion ($2.37 billion).
Street expects SIEGY's revenue for the fiscal year (ending September 2024) to increase 2% year-over-year to $86.02 billion. The company's EPS for the current year is expected to grow 70.9% year-over-year to $9.68. Moreover, the company topped the EPS estimates in each of the trailing four quarters, which is excellent.
Shares of SIEGY have surged 38.9% over the past year to close the last trading session at $101.06.
It is no surprise that SIEGY has an overall rating of B, equating to Buy in our POWR Ratings system. It also has a B grade for Value, Stability, and Sentiment. Out of 34 stocks in the B-rated <a href="https://stocknews.com/category/industrial-manufacturing/">Industrial – Manufacturing</a> industry, it is ranked #3.
In addition to the POWR Rating grades I've just highlighted, you can see SIEGY's Growth, Momentum, and Quality ratings <a href="https://stocknews.com/stock/SIEGY/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
NVS shares were trading at $114.29 per share on Tuesday afternoon, down $0.73 (-0.63%). Year-to-date, NVS has gained 15.94%, versus a 20.62% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/nvs-ul-siegy-3-european-stocks-to-watch-as-the-eu-economy-strengthens/>3 European Stocks to Watch as the EU Economy Strengthens</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 European Stocks to Watch as the EU Economy Strengthens

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the market. Amid this backdrop, it could be wise to scoop up the shares of fundamentally sound pharma stocks like AbbVie (ABBV), Novartis (NVS), and Pfizer (PFE), which are not just attractive due to their high dividends but are also trading at discounts. Keep reading… As investors await the Federal Reserve's upcoming two-day meeting, all eyes are on the first potential interest rate cut in over four years. While a rate cut is typically intended to stimulate economic growth, it also reflects deeper concerns about the broader economy's health.
Given the uncertainty in the air, investors could consider investing in high-dividend pharmaceutical stocks like AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>), and Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>) that are trading at discounts. These blue-chip giants are known for their financial robustness and history of reliable returns to shareholders, making them excellent options for both seasoned and newer investors seeking stable growth.
Healthcare, unlike other sectors, remains resilient in the face of economic fluctuations due to the consistent demand for medicines and treatments. The Centers for Medicare &amp; Medicaid Services (CMS) project U.S. healthcare spending to climb, with national expenditures expected to hit <a href="https://www.pgpf.org/blog/2024/09/healthcare-spending-will-be-one-fifth-of-the-economy-within-a-decade">$7.7 trillion by 2032</a>. This growing demand, paired with an aging population, ensures that companies in the healthcare and pharmaceutical sectors are well-positioned for long-term growth.  
With that in mind, let's examine the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry picks in detail, beginning with the third choice:
Stock #3: Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE is a global leader in biopharmaceuticals, offering a wide range of medicines and vaccines across several therapeutic areas. Its diverse portfolio spans treatments for cardiovascular conditions, metabolic issues, migraines, women's health, and infectious diseases, including COVID-19 prevention and treatment.
On August 27, the company introduced PfizerForAll, a digital platform designed to make access to healthcare and managing health and wellness more seamless for Americans. The platform supports common illnesses like migraines, COVID-19, and flu, as well as adult vaccinations. It integrates with the existing healthcare system and partners to streamline access and address gaps in care.
On July 25, PFE received conditional marketing authorization from the European Commission for DURVEQTIX, a gene therapy for severe Hemophilia B in adults, promising a one-time dose to reduce or eliminate bleeding.
With 13 years of consecutive dividend growth, the company pays an annual dividend of $1.68 per share, which translates to a yield of 5.59% on the current share price. Its four-year average yield is 4.17%. PFE's dividend payout has grown at a CAGR of 4.4% over the past five years.
In terms of forward non-GAAP P/E, PFE is trading at 11.39x, 47.1% lower than the industry average of 21.51x. Likewise, the stock's forward EV/EBITDA and Price/Cash Flow multiples of 10.46 and 9.28 are 25.2% and 42.6% lower than the industry averages of 13.99x and 16.17x, respectively.
PFE's revenues for the second quarter (ended June 30, 2024) increased 2.1% year-over-year to $13.28 billion. Its adjusted <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> and adjusted EPS attributable stood at $3.40 billion and $0.60, respectively.
The company has updated its fiscal year 2024 financial guidance, increasing its revenue projection to a range of $59.50 billion to $62.50 billion from the previous estimate of $58.50 billion to $61.50 billion. Additionally, it has raised its adjusted EPS guidance to a new range of $2.45 to $2.65, higher than the prior forecast of $2.15 to $2.35.
Analysts expect PFE's revenue for the fourth quarter (ending December 2024) to grow 26.3% year-over-year to $18 billion, while its EPS for the same period is expected to increase considerably from the prior year to $0.67. Also, it topped the EPS estimates in each of the trailing four quarters.
PFE shares have surged 12.9% over the past nine months to close the last trading session at $30.07.
PFE's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
PFE also has a B grade for Growth and Value. It is ranked #48 out of 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/PFE/">Click here</a> to see PFE's ratings for Momentum, Stability, Sentiment, and Quality.
Stock #2: Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>)
Headquartered in Basel, Switzerland, NVS researches, develops, manufactures, and markets healthcare products worldwide through two segments: Innovative Medicines and Sandoz.
On August 28, the company's subsidiary Novartis Pharma AG entered into a global licensing agreement with Lindy Biosciences to access its innovative microglassification technology for biologic drugs. This partnership grants NVS exclusive global rights across multiple biologic targets, focusing on developing high-concentration, self-administered treatments.
The collaboration aims to improve patient outcomes and compliance by enabling at-home treatments. Further, it strengthens the company's position in innovative drug delivery and enhances its ability to offer patient-friendly solutions.
NVS pays an annual dividend of $3.74 per share, translating to a yield of 3.20% at the current price level, while its four-year average yield is 3.49%. Its dividend payouts have increased at a 7.3% CAGR over the past three years and a 6.9% CAGR over the past five years.
In terms of forward non-GAAP P/E, NVS is trading at 15.68x, which is 27.1% lower than the industry average of 21.51x. Also, its forward EV/EBIT ratio of 13.79x is 18.4% below the industry average of 16.90x.
In the fiscal second quarter that ended June 30, 2024, NVS' net sales increased 9.4% year-over-year to $12.51 billion. Its operating income from continuing operations grew 43% from the year-ago value to $4.01 billion. The company's net income and EPS came in at $3.25 billion and $1.60, representing a 40.1% and 44.1% year-over-year improvement, respectively. In addition, its free cash flow stood at $4.62 billion, up 40.9% year-over-year.
The consensus EPS estimate of $1.96 for the fiscal third quarter (ending September 2024) represents a 12.5% improvement year-over-year. The consensus revenue estimate of $12.52 billion for the ongoing quarter represents a 6.3% increase from last year. The company has an impressive surprise history; it surpassed the consensus revenue estimates in three of the trailing four quarters.
Shares of NVS have gained 20.1% over the past nine months and 15.8% year-to-date to close the last trading session at $116.95.
It is no surprise that NVS has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. It has a B grade for Growth, Value, Stability, and Quality. Within the same industry, it is ranked #3.
In addition to the POWR Rating grades I've just highlighted, you can see NVS' Momentum and Sentiment ratings <a href="https://stocknews.com/stock/NVS/">here</a>.
Stock #1: AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>)
ABBV is a global diversified research-based biopharmaceutical company engaged in manufacturing and selling medications and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties.
On September 06, the company declared a quarterly dividend of $1.55 per share, payable to its shareholders on November 15, 2024. Its forward annual dividend of $6.20 translates to a 3.17% yield on current prices. ABBV's four-year average dividend yield is 4.01%.
Its dividends have grown at 6.5% and 8% CAGRs over the past three and five years, respectively. Also, it has a record of 10 years of consecutive dividend growth.
On August 01, ABBV announced the acquisition of Cerevel Therapeutics (<a href="https://stocknews.com/stock/CERE/">CERE</a>) to strengthen its position in neuroscience and expand its portfolio in psychiatry, migraine, and Parkinson's disease, bolstering its existing pipeline and market presence.
In terms of forward non-GAAP P/E, ABBV is trading at 17.98x, 16.4% lower than the industry average of 21.51x. Likewise, the stock's forward EV/EBIT multiple of 16.25 is below its industry average of 16.90 by 3.9%.
For the six-month period that ended on June 30, 2024, ABBV's net revenue increased 2.6% year-over-year to $26.77 billion, while the company's Neuroscience segment reported net revenue of $4.13 billion, indicating a 15.3% growth from the prior-year quarter. ABBV's attributable net income came in at $2.74 billion, up 21% year-over-year, while its earnings per share attributable grew 21.4% from the year-ago value to $1.53.
Looking ahead, ABBV forecasts full-year 2024 and raises its adjusted EPS to range between $10.71 and $10.91, from the prior forecast of $10.61 and $10.81.
Street expects ABBV's revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 2.4% and 5.7% year-over-year to $14.64 billion and $2.95, respectively. Moreover, it beat the revenue estimates in each of the trailing four quarters, which is promising.
Over the past year, the stock has gained 28.7%, closing the last trading session at $195.73.
ABBV's strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has a B grade for Growth, Value, Stability, Sentiment, and Quality. Out of 161 stocks in the Medical - Pharmaceuticals industry, ABBV is ranked #2. <a href="https://stocknews.com/stock/ABBV/">Click here</a> to see ABBV's rating for Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
ABBV shares were trading at $192.84 per share on Tuesday afternoon, down $2.89 (-1.48%). Year-to-date, ABBV has gained 27.96%, versus a 19.14% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/abbv-pfe-nvs-cere-3-high-dividend-pharma-blue-chips-that-are-on-sale-right/>3 High-Dividend Pharma Blue Chips That Are on Sale Right Now</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Dividend Pharma Blue Chips That Are on Sale Right Now

As Europe navigates a complex landscape of slowing inflation, stable employment, and modest GDP growth, it may be an opportune time for investors to consider investing in quality stocks like Novo Nordisk (NVO), SAP SE (SAP), and Novartis (NVS), which are poised to capitalize on the continent's recovery. Read on… As Europe's economy shows signs of recovery amid ongoing challenges, fundamentally sound companies like Novo Nordisk A/S (<a href="https://stocknews.com/stock/NVO/">NVO</a>), SAP SE (<a href="https://stocknews.com/stock/SAP/">SAP</a>), and Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>) could offer strong investment potential as they benefit from broader macroeconomic trends.
The European Central Bank (ECB) recently <a href="https://www.theguardian.com/business/2024/sep/12/economic-growth-in-eurozone-will-be-weaker-than-hoped-says-ecb">lowered its deposit facility rate</a> for the second time this year in response to slowing inflation. Inflation in the eurozone dropped to 2.2% in August, edging closer to the ECB's 2% target. However, the continent's economic recovery remains tepid, with GDP growth forecast at 0.8% this year and slight improvements expected through 2026.
Economic growth in the eurozone saw an uptick in the second quarter of 2024, with <a href="https://ec.europa.eu/eurostat/web/products-euro-indicators/w/2-14082024-ap#:~:text=In%20the%20second%20quarter%20of,by%200.3%25%20in%20both%20zones.">GDP increasing by 0.3%</a>, supported by rising employment and steady consumer demand. Moreover, employment rates have also grown by 0.2% across the euro area, further indicating that the labor market is stabilizing, providing a foundation for continued economic expansion.
While financial markets expect further rate cuts from the ECB, signaling some uncertainty in the recovery's pace, Europe's economic fundamentals remain sound enough to support gradual improvement.
Given this backdrop, companies like NVO, SAP, and NVS seem well-positioned to benefit from the continent's improving economic landscape. Let's delve into the fundamental aspects of these stocks in detail:
Novo Nordisk A/S (<a href="https://stocknews.com/stock/NVO/">NVO</a>)
Headquartered in Bagsvaerd, Denmark, NVO is a global healthcare company engaged in discovering, developing, manufacturing, and marketing pharmaceutical products. It operates through two business segments: Diabetes and Obesity care; and Biopharm.
On June 24, NVO announced a $4.1 billion investment to expand US manufacturing capacity by building a second fill and finishing manufacturing facility in Clayton, North Carolina. This will grow the facility's ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
For the first half of the year that ended June 30, 2024, NVO's net sales increased 23.9% year-over-year to Kr133.41 billion ($19.87 billion), while its operating profit came in at Kr57.78 billion ($8.61 billion) up 18.2% year-over-year. The company's net profit came in at Kr45.46 billion ($6.77 billion) and Kr10.17 per share, representing 15.8% and 16.8% increases year-over-year, respectively.
Street expects NVO's revenue and <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> for the fiscal third quarter (ending September 2024) to increase 30% and 21.3% year-over-year to $10.87 billion and $0.86, respectively. Moreover, it beat the revenue estimates in each of the trailing four quarters, which is promising.
Over the past year, the stock has gained 43.8%, closing the last trading session at $136.90.
NVO's promising fundamentals are apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
It has an A grade for Quality and is ranked #24 out of 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/NVO/">Click here</a> to see the additional ratings for NVO (Growth, Value, Momentum, Stability, and Sentiment).
SAP SE (<a href="https://stocknews.com/stock/SAP/">SAP</a>)
SAP is a Germany-based company that offers enterprise application software. It operates through three segments: Applications, Technology &amp; Services; the SAP Business Network; and the Customer Experience.
On September 12, the company completed its acquisition of WalkMe Ltd. (<a href="https://stocknews.com/stock/WKME/">WKME</a>) for $1.5 billion in an all-cash deal. WKME's digital adoption platform will enhance SAP's Business Transformation Management portfolio, including SAP Signavio and SAP LeanIX, by improving workflow execution and user experience. Its AI technology will also power SAP's Joule copilot, offering context-aware assistance to boost workflow productivity.
SAP's total revenue for the second quarter (ended June 30, 2024) increased 8.9% year-over-year to €16.33 billion ($18.15 billion). Its gross profit grew 10.1% from the year-ago value to €11.78 billion ($13.09 billion).
The company's cash inflow from operating activities amounted to €4.29 billion ($4.78 billion), representing a 35.9% increase from the same period last year. Also, its free cash flow stood at €3.78 billion ($4.21 billion), up 47.9% year-over-year.
Analysts expect SAP's revenue for the fourth quarter (ending December 2024) to grow 9.1% year-over-year to $10.02 billion, while its EPS for the same period is expected to increase 2.9% from the prior year to $1.57. Also, it topped the revenue estimates in three of the trailing four quarters.
The stock has gained 65.3% over the past year to close the last trading session at $223.60.
SAP's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has a B grade for Stability, Sentiment, and Quality. Out of 126 stocks in the <a href="https://stocknews.com/category/software-application/">Software – Application</a> industry, SAP is ranked #27. <a href="https://stocknews.com/stock/SAP/">Click here</a> to see SAP's Growth, Value, and Momentum ratings.
Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>)
Headquartered in Basel, Switzerland, NVS researches, develops, manufactures, and markets healthcare products worldwide through two segments: Innovative Medicines and Sandoz.
On August 28, the company's subsidiary Novartis Pharma AG entered into a global licensing agreement with Lindy Biosciences to access its innovative microglassification technology for biologic drugs. This partnership grants NVS exclusive global rights across multiple biologic targets, focusing on developing high-concentration, self-administered treatments.
The collaboration aims to improve patient outcomes and compliance by enabling at-home treatments. Further, it strengthens the company's position in innovative drug delivery and enhances its ability to offer patient-friendly solutions.
In the fiscal second quarter that ended June 30, 2024, NVS' net sales increased 9.4% year-over-year to $12.51 billion. Its operating income from continuing operations grew 43% from the year-ago value to $4.01 billion. The company's net income and EPS came in at $3.25 billion and $1.60, representing a 40.1% and 44.1% year-over-year improvement, respectively. In addition, its free cash flow stood at $4.62 billion, up 40.9% year-over-year.
The consensus EPS estimate of $1.96 for the fiscal third quarter (ending September 2024) represents a 12.5% improvement year-over-year. The consensus revenue estimate of $12.52 billion for the ongoing quarter represents a 6.3% increase from last year. The company has an impressive surprise history; it surpassed the consensus revenue estimates in three of the trailing four quarters.
Shares of NVS have gained 20.1% over the past nine months and 15.8% year-to-date to close the last trading session at $116.95.
It is no surprise that NVS has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. It has a B grade for Growth, Value, Stability, and Quality. Within the Medical - Pharmaceuticals industry, it is ranked #3 out of 161 stocks.
In addition to the POWR Rating grades I've just highlighted, you can see NVS' Momentum and Sentiment ratings <a href="https://stocknews.com/stock/NVS/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
NVO shares were trading at $132.76 per share on Tuesday afternoon, down $4.14 (-3.02%). Year-to-date, NVO has gained 29.33%, versus a 19.10% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/nvo-sap-nvs-wkme-3-european-stocks-to-buy-as-the-continents-economy-recovers/>3 European Stocks to Buy as the Continent's Economy Recovers</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 European Stocks to Buy as the Continent's Economy Recovers

Goldman Sachs analyst James Quigley maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF104.00. Qui...

Goldman Sachs Remains a Hold on Novartis AG (NOVN)

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

U.S. tweaks 2025 Medicare price negotiation process

BNY Mellon International Equity Fund Q2 2024 Commentary

Wells Fargo's 'Core' stocks: GOOGL, HD, KO, and more

AAPL

ABBV

AMGN

ATEYY

AVGO

BKAG

BKCI

BKEM

BKGI

BKHY

BKIE

BKLC

BKMC

BKSE

BKUI

BMYMP

CATX

CERE

CMCSA

CNVVF

CSCO

EXPGF

GOOGL

LSTR

LVMHF

MSFT

NSRGY

NVSEF

ORCL

PAYX

RCRRF

SBUX

SIEGY

SZCRF

TCCPY

WKME

Press Releases

Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation

Financing

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

Small Cap

Opinion

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

AMGEN

AMRX

ANVS

BMRN

GLMD

KTRA

LNTH

NTRB

NTRBW

ONCY

STRO

TEVA

TSX:ONC

TSX:RKV

TSXV:RKV

XBIT

ZYME

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical

Comments

Novartis

뉴스

에 대한 최신 뉴스 Novartis (NYSE:NVS) 주식

목요일, 7월 18, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌